By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – French firm Cellectis and North Carolina-based Precision Biosciences have filed two new suits against each other alleging infringement of US patents covering modified meganucleases.
Helix will promote Cellectis' Genome Positioning System line of products and services in India.
The French firm gains access to Cyto Pulse's electroporation technologies and equipment.
Cedarlane will distribute Cellectis Bioresearch's kits in Canada.
The patent has been the subject of ongoing litigation between the French and US biotech firms.
The agricultural products company will use Cellectis' meganuclease tools and will invest in the French firm.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.